Lindbrook Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Lindbrook Capital’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$2.72K	Hold	164	–	–	﹤0.01%	2190
2024 Q4	$3.01K	Buy	164 +38	+30%	+$613	﹤0.01%	2175
2024 Q3	$1.94K	Buy	126 +34	+37%	+$567	﹤0.01%	2355
2024 Q2	$1.5K	Sell	92 -19	-17%	-$307	﹤0.01%	2419
2024 Q1	$2.05K	Buy	111 +2	+2%	+$50	﹤0.01%	2228
2023 Q4	$3.41K	Sell	109 -23	-17%	-$549	﹤0.01%	2073
2023 Q3	$2.75K	Buy	132 +24	+22%	+$652	﹤0.01%	2008
2023 Q2	$2.59K	Buy	108 +16	+17%	+$356	﹤0.01%	2049
2023 Q1	$1.73K	Hold	92	–	–	﹤0.01%	2302
2022 Q4	$1.47K	Sell	92 -304	-77%	-$4.75K	﹤0.01%	2367
2022 Q3	$6K	Buy	396 +266	+205%	+$4.31K	﹤0.01%	1537
2022 Q2	$2K	Sell	130 -37	-22%	-$691	﹤0.01%	1891
2022 Q1	$4K	Buy	167 +68	+69%	+$1.65K	﹤0.01%	1661
2021 Q4	$2K	Hold	99	–	–	﹤0.01%	1737
2021 Q3	$2K	Buy	+99	New	+$1.91K	﹤0.01%	1487
2021 Q2	–	Sell	-65	Closed	-$2K	–	1899
2021 Q1	$2K	Buy	65 +53	+442%	+$2.33K	﹤0.01%	1504
2020 Q4	$1K	Buy	+12	New	+$596	﹤0.01%	1557

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Lindbrook Capital's ACAD Position: Q1 2025 in Review

Lindbrook Capital held its Acadia Pharmaceuticals (ACAD) position steady in Q1 2025 at 164 shares worth $2.72K. The position accounts for ﹤0.01% of the portfolio, ranked #2190.

Lindbrook Capital first reported a position in ACAD in Q4 2020 and has held it in 17 quarters since. The position peaked at $6K in Q3 2022. 320 funds tracked by Wall St. Rank hold ACAD as of Q1 2025.

Lindbrook Capital held 164 shares of Acadia Pharmaceuticals worth $2.72K as of Q1 2025.
Lindbrook Capital left its Acadia Pharmaceuticals share count unchanged in Q1 2025.
Acadia Pharmaceuticals made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2190 holding.
Lindbrook Capital first reported a position in Acadia Pharmaceuticals in Q4 2020 and has held it in 17 quarters since.
Lindbrook Capital's Acadia Pharmaceuticals position peaked at $6K in Q3 2022.
320 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.